About Artelo Biosciences, Inc.
https://www.artelobio.comArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.
CEO
Gregory D. Gorgas
Compensation Summary
(Year 2024)
Salary $520,000
Bonus $242,450
Option Awards $240,016
All Other Compensation $58,004
Total Compensation $1,060,470
Industry Biotechnology
Sector Healthcare
Went public June 21, 2019
Method of going public IPO
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-13 | Reverse | 1:6 |
| 2022-08-10 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Hold 2
Showing Top 3 of 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.74%
Total Number Of Holders 1
Showing Top 1 of 1
Market Cap $3.23 M
52w High $28.60
52w Low $1.15
P/E -0.09
Volume 354.79K
Outstanding Shares 2.02M
About Artelo Biosciences, Inc.
https://www.artelobio.comArtelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.09M ▼ | $-3.12M ▲ | 0% | $-3.97 ▲ | $-3.01M ▲ |
| Q2-2025 | $0 | $3.15M ▲ | $-3.22M ▼ | 0% | $-5.61 ▼ | $-3.15M ▼ |
| Q1-2025 | $0 | $2.38M ▼ | $-2.37M ▲ | 0% | $-0.72 ▲ | $-2.38M ▲ |
| Q4-2024 | $0 | $3.81M ▲ | $-3.78M ▼ | 0% | $-7 ▼ | $-3.81M ▼ |
| Q3-2024 | $0 | $1.2M | $-1.13M | 0% | $-0.35 | $-1.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.72M ▼ | $4.27M ▼ | $4.9M ▼ | $-633K ▲ |
| Q2-2025 | $2.07M ▲ | $4.36M ▲ | $5.76M ▲ | $-1.41M ▼ |
| Q1-2025 | $746K ▼ | $3.52M ▼ | $2.86M ▲ | $652K ▼ |
| Q4-2024 | $2.34M ▼ | $4.7M ▼ | $1.84M ▲ | $2.86M ▼ |
| Q3-2024 | $4.86M | $7.14M | $775K | $6.36M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.12M ▲ | $-3.5M ▼ | $-250K ▼ | $3.44M ▲ | $-346K ▼ | $-3.5M ▼ |
| Q2-2025 | $-3.99M ▼ | $-514K ▲ | $0 | $1.82M ▲ | $1.32M ▲ | $-514K ▲ |
| Q1-2025 | $-2.37M ▲ | $-1.6M ▲ | $0 ▼ | $0 ▼ | $-1.59M ▲ | $-1.6M ▲ |
| Q4-2024 | $-3.78M ▼ | $-2.57M ▼ | $500K ▼ | $57K ▲ | $-2.02M ▼ | $-2.57M ▼ |
| Q3-2024 | $-2.28M | $-858.43K | $4.34M | $794.5 | $3.48M | $-1.97M |
CEO
Gregory D. Gorgas
Compensation Summary
(Year 2024)
Salary $520,000
Bonus $242,450
Option Awards $240,016
All Other Compensation $58,004
Total Compensation $1,060,470
Industry Biotechnology
Sector Healthcare
Went public June 21, 2019
Method of going public IPO
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-13 | Reverse | 1:6 |
| 2022-08-10 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Hold 2
Showing Top 3 of 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
Summary
% Of Shares Owned 0.74%
Total Number Of Holders 1
Showing Top 1 of 1